MedTrace Logo

Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy

NCT06382103 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2025-03-26

No results posted yet for this study

Summary

Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to potentially improve prediction of long term prognosis and guide treatment options of patients with hepatocellular carcinoma underwent surgical resection.

Conditions

Interventions

DIAGNOSTIC_TEST

ctDNA monitoring

The ctDNA level will be measured using tumor-informed (Signatera platform) and tumor-naived (fragmentomes measurement) assay.

DIAGNOSTIC_TEST

Plasma proteomic analysis

plasma protein level will be measured via Proximity Extension Assay and LC-MS based proteomic analysis

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-15
Primary Completion
2025-05-20
Completion
2026-05-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06382103 on ClinicalTrials.gov